Coalition for Epidemic Preparedness Innovations   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Oslo Norway (2017)

Organization Overview

First Clinical Trial
2019
NCT03805984
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Coalition for epidemic prepardness innovations | Coalition for Epidemic Preparedness Initiative (CEPI) | Coalition for Epidemic Preparedness Innovations | Coalition for Epidemic Preparedness Innovations (CEPI) | Coalition of Epidemic Preparedness Innovations (CEPI) | The Coalition for Epidemic Preparedness Innovations | The Coalition for Epidemic Preparedness Innovations (CEPI)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronavirus Infections (Phase 2)

Hemorrhagic Fever, Ebola (Phase 3)

Henipavirus Infections (Phase 1)

Infections (Phase 1)

Lassa Fever (Phase 1)

Severe Acute Respiratory Syndrome (Phase 2)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 32
  • # of Trial APIs: 35